They further demonstrated that the combined MEK and ERBB inhibition using the MEK inhibitor selumetinib and the pan-ERBB inhibitor neratinib of human organoid orthotopic xenografts resulted in tumor regression in short-term intervention studies [66]. The gene discussed is EGFR; the disease is neoplasm.